Search results
Results from the WOW.Com Content Network
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
1997: Enhancement of the biotechnology department. 2010: The institute produced 1.7 billion doses of 57 types of vaccines, serums, and antigens per year. 2012: Production of transgenic animals , creating recombinant vaccines through genetic engineering, developing antigens and diagnostic kits for medical and veterinary labs.
[19] [25] In 2022, Massachusetts biotechnology companies raised $8.7 billion in venture capital in a 37% decrease from the previous year, while during the first half of 2023, Massachusetts biotechnology companies raised $3.7 billion in venture capital financing in a 27% decrease from the $5.1 billion raised during first half of 2022.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Guardant Health sued Foundation Medicine over patents in 2019–2020. [49] [50] In 2021, Guardant Health licensed intellectual property to Foundation Medicine for $25 million in a settlement. [51] In 2022, Illumina sued Guardant Health and its co-founders in Delaware federal court over trade secrets. Illumina accused the duo of incorporating ...
United Therapeutics Corporation is an American publicly traded biotechnology company [2] and public benefit corporation [3] listed on the NASDAQ under the symbol UTHR. [4] [5] It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing.
Another $60 million in new Series D financing was raised in 2022. [23] As of 2023 [update] it was reported that over $400 million had been invested in the company. [ 28 ] In 2023, Zhavoronkov stated that he "moved the company's R&D to China to capitalize on 'half a trillion dollars' worth of infrastructure and hundreds of thousands of ...